The Westminster lensArchive · Written questions · 12 tabled · 12 answered

Written questions by Sullivan.

Every parliamentary written question tabled by Lauren Sullivan this session, with the full answer and department. Back to the MP page.

Department:All (12)Department for Business and Trade (2)Department for Environment, Food and Rural Affairs (2)Department of Health and Social Care (2)Department for Work and Pensions (1)Wales Office (1)Foreign, Commonwealth and Development Office (1)Home Office (1)Ministry of Justice (1)Department for Transport (1)

Showing 12 of 2 · Department of Health and Social Care

21 Feb 2025·Department of Health and Social Care·Answered
Asked

What assessment he has made of the merits of bringing forward legislative proposals on regulating sports therapists.

Reply

The Government has no current plans to extend statutory regulation to sports therapists. The Professional Standards Authority for Health and Social Care (PSA) operates a voluntary registers programme, which provides a proportionate means of assurance for unregulated professions, that sits between employer controls and statutory regulation by setting standards for organisations holding voluntary registers for unregulated health and social care occupations. There are currently two voluntary registers for organisations relating to sports therapy accredited by the PSA.

21 Feb 2025·Department of Health and Social Care·Answered
Asked

What steps he is taking to help ensure patients with vitiligo have access to effective treatments in the context of NICE's decision not to recommend Ruxolitinib for NHS use.

Reply

The Government wants National Health Service patients to be able to benefit from access to clinically and cost-effective new treatments, and the National Institute for Health and Care Excellence (NICE) makes recommendations for the NHS on whether new medicines should be routinely funded by the NHS based on an assessment of their costs and benefits. The NICE is currently developing guidance for the NHS on whether ruxolitinib should be routinely funded by the NHS, based on an assessment of its costs and benefits.The NICE was unfortunately unable to recommend ruxolitinib as a clinically and cost-effective use of NHS resources in its final draft guidance published on 18 July. The NICE received four appeals against its draft recommendation which were heard by an independent panel on 11 October 2024. The appeal panel remitted the evaluation of ruxolitinib to the appraisal committee with the instruction to take all reasonable steps to address the issues raised in the upheld appeal points. The committee will consider the upheld appeal points at a future meeting scheduled for 14 May 2025.It is right that the NICE makes its decisions at arm’s length of the Government and in line with its carefully developed methods and processes. As such, it would not be appropriate for me to intervene in the NICE’s decision-making.

Sources
SourceUK Parliament Members API
MethodQuestion and answer text as published. Question preamble (“To ask the…”) trimmed for readability; answers shown in full.